This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Emma Kelsall
Scientist I at AstraZeneca


Emma joined the Cell Line Development and Engineering team at AstraZeneca in 2017 following PhD and Postdoctoral studies at the University of Leicester, UK. The Cell Line Development team are responsible for generating the manufacturing clonal cell lines for biotherapeutic production and technology development of the CLD platform process. Emma is currently leading investigations into the next generation of biotherapeutic expression vectors and improving the expression and product quality of difficult to express proteins using novel approaches.

Agenda Sessions

  • Using mass spectrometry and next gen sequencing to detect and understand the mechanism of sequence variants